Search results
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 6 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Medscape· 3 days agoEncouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis...
This startup uses overseas freelancers to help Americans find Adderall and Ozempic
Quartz· 2 days agoA startup is working to help Americans navigate ongoing shortages of highly-coveted drugs like...
Why Regeneron Stock Finally Joined The 1,000-Club
Investor's Business Daily· 18 hours agoEnthusiasm is growing for a looming approval in COPD treatment.
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 6 days agoRecap of the Week’s Most Important Stories Lilly’s CFO Departs: Lilly’s executive vice president and...
Experts Focus on Quality-of-Life Data in Prostate Cancer
Medscape· 2 days agoSeveral trials presented at ASCO 2024 explored strategies to improve quality of life in patients with prostate cancer.
Ongoing Efforts to Expand Kidney Donor Pool Seem Mostly Safe
Medscape· 1 day agoLiving donors had a similar risk for hypertension and albuminuria after donation as nondonors, and...
State Drug Pricing Boards Forge Ahead With Eyes on Amgen Suit
Bloomberg Law· 3 days agoState affordability boards seeking to limit what health plans pay for prescription drugs are confident they will withstand legal challenges as Colorado battles what’s expected to be the first ...
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
Zacks via Yahoo Finance· 3 days agoModerna is also evaluating mRNA-1345 in early-stage studies for high-risk adults, as well as...
A Deep Dive into the New Amplify Weight Loss Drug & Treatment ETF (THNR) | Investing.com
Investing.com· 3 days agoETF investors are quick to jump from one trend to another, and the latest focus is on companies...